Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Hanley

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Transplantation and Cellular Therapy|November 17, 2021
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation RecipientsJeremy D Rubinstein, Sonata Jodele, Daria Heyenbruch, et al.
Cytotherapy|April 15, 2014
Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion SystemPatrick J Hanley, Zhuyong Mei, April G Durett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2019
Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I StudyAmy B Hont, C Russell Cruz, Robert Ulrey, et al.
Nature Communications|March 30, 2024
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complicationMichael D Keller, Stefan A Schattgen, Shanmuganathan Chandrakasan, et al.
Blood Advances|July 12, 2019
Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipientsAllistair A Abraham, Tami D John, Michael D Keller, et al.
Cytotherapy|April 7, 2024
Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related productsMark D Stewart, Michael Kalos, Vicki Coutinho, et al.
Blood Advances|February 2, 2022
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplantJeremy D Rubinstein, Carolyn Lutzko, Thomas Leemhuis, et al.
JACC. Basic to Translational Science|January 11, 2024
Mesenchymal Stromal Cell Delivery Via Cardiopulmonary Bypass Provides Neuroprotection in a Juvenile Porcine ModelKamil Sarkislali, Kei Kobayashi, Nemanja Sarić, et al.
Science Translational Medicine|May 1, 2015
CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivoPatrick J Hanley, Jan J Melenhorst, Sarah Nikiforow, et al.
Blood Advances|September 2, 2021
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restrictedJeremy D Rubinstein, Xiang Zhu, Thomas Leemhuis, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Transplantation and Cellular Therapy|November 17, 2021
Off-the-Shelf Third-Party Virus-Specific T Cell Therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem Cell Transplantation RecipientsJeremy D Rubinstein, Sonata Jodele, Daria Heyenbruch, et al.
Cytotherapy|April 15, 2014
Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion SystemPatrick J Hanley, Zhuyong Mei, April G Durett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2019
Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I StudyAmy B Hont, C Russell Cruz, Robert Ulrey, et al.
Nature Communications|March 30, 2024
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complicationMichael D Keller, Stefan A Schattgen, Shanmuganathan Chandrakasan, et al.
Blood Advances|July 12, 2019
Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipientsAllistair A Abraham, Tami D John, Michael D Keller, et al.
Cytotherapy|April 7, 2024
Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related productsMark D Stewart, Michael Kalos, Vicki Coutinho, et al.
Blood Advances|February 2, 2022
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplantJeremy D Rubinstein, Carolyn Lutzko, Thomas Leemhuis, et al.
JACC. Basic to Translational Science|January 11, 2024
Mesenchymal Stromal Cell Delivery Via Cardiopulmonary Bypass Provides Neuroprotection in a Juvenile Porcine ModelKamil Sarkislali, Kei Kobayashi, Nemanja Sarić, et al.
Science Translational Medicine|May 1, 2015
CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivoPatrick J Hanley, Jan J Melenhorst, Sarah Nikiforow, et al.
Blood Advances|September 2, 2021
Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restrictedJeremy D Rubinstein, Xiang Zhu, Thomas Leemhuis, et al.
Pageof 10